Syndax Pharma (SNDX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec8

Syndax Pharmaceuticals Announces Positive Trial Results for Revuforj® in AML at ASH Annual Meeting

11:50

Nov24

Barclays Maintains Overweight Rating and Raises Target Price for Syndax Pharmaceuticals

18:57

Nov14

H.C. Wainwright and J.P. Morgan Reiterate Buy Rating on Syndax Pharmaceuticals

11:42

Nov4

Syndax Pharmaceuticals Reports Exceeding EPS Expectations for Q3, Stock Price Rises

17:23

Lawson Reiterates Buy Rating on Syndax Pharmaceuticals

07:56

Syndax Pharma released FY2025 9 Months Earnings on November 3 After-Market EST, with actual revenue of USD 58 M and EPS of USD -1.8167

00:00

Schedules & Filings

Schedules

Filings

Nov3

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 45.87 M, Net Income -60.72 M, EPS -0.7009

Aug4

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 37.96 M, Net Income -71.85 M, EPS -0.8321

May5

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 20.04 M, Net Income -84.85 M, EPS -0.9846

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change